Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats

R. Vinitha, Muthusamy Thangaraju, P. Sachdanandam

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Tamoxifen, a non-steroidal anti-oestrogen, is used in the treatment of breast cancer, both receptor positive and negative tumours. It also possesses weak oestrogenic activity which forms the basis of this study. Tamoxifen (2 different dosages) was administered through diet (10 mg/kg diet and 20 mg/kg diet) to experimental atherosclerosis induced female rats to assess the effect of tamoxifen on plasma lipid levels, lipoprotein cholesterol level and on the activity of lipid metabolising enzymes. The plasma total lipid level was increased in atherosclerosis suffering animals compared to control animals with concomitant changes in the activity of lipid metabolising enzymes. HDL-cholesterol was decreased while LDL-cholesterol and VLDL-cholesterol were increased in the atherosclerosis induced group. Cholesterol and free cholesterol were decreased in tamoxifen treated groups while the other lipids show a moderate increase. HDL-cholesterol was increased but LDL-cholesterol was decreased in the tamoxifen treated groups. The higher dosage tamoxifen given group animals show significantly favourable results from therapy stand point when compared to diseased group.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalMolecular and Cellular Biochemistry
Volume168
Issue number1-2
StatePublished - Mar 6 1997

Fingerprint

Tamoxifen
Wistar Rats
Rats
Atherosclerosis
Lipids
Enzymes
Nutrition
Animals
Diet
LDL Cholesterol
HDL Cholesterol
Non-Steroidal Estrogens
Cholesterol
Plasmas
VLDL Cholesterol
Tumors
Estrogens
Breast Neoplasms
Neoplasms

Keywords

  • Atherosclerosis
  • Enzymes
  • Lipoprotein cholesterol
  • Oestrogen
  • Plasma lipids
  • Tamoxifen

ASJC Scopus subject areas

  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats. / Vinitha, R.; Thangaraju, Muthusamy; Sachdanandam, P.

In: Molecular and Cellular Biochemistry, Vol. 168, No. 1-2, 06.03.1997, p. 13-19.

Research output: Contribution to journalArticle

@article{32ad44a13d584b94aff4e859a7269f13,
title = "Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats",
abstract = "Tamoxifen, a non-steroidal anti-oestrogen, is used in the treatment of breast cancer, both receptor positive and negative tumours. It also possesses weak oestrogenic activity which forms the basis of this study. Tamoxifen (2 different dosages) was administered through diet (10 mg/kg diet and 20 mg/kg diet) to experimental atherosclerosis induced female rats to assess the effect of tamoxifen on plasma lipid levels, lipoprotein cholesterol level and on the activity of lipid metabolising enzymes. The plasma total lipid level was increased in atherosclerosis suffering animals compared to control animals with concomitant changes in the activity of lipid metabolising enzymes. HDL-cholesterol was decreased while LDL-cholesterol and VLDL-cholesterol were increased in the atherosclerosis induced group. Cholesterol and free cholesterol were decreased in tamoxifen treated groups while the other lipids show a moderate increase. HDL-cholesterol was increased but LDL-cholesterol was decreased in the tamoxifen treated groups. The higher dosage tamoxifen given group animals show significantly favourable results from therapy stand point when compared to diseased group.",
keywords = "Atherosclerosis, Enzymes, Lipoprotein cholesterol, Oestrogen, Plasma lipids, Tamoxifen",
author = "R. Vinitha and Muthusamy Thangaraju and P. Sachdanandam",
year = "1997",
month = "3",
day = "6",
language = "English (US)",
volume = "168",
pages = "13--19",
journal = "Molecular and Cellular Biochemistry",
issn = "0300-8177",
publisher = "Springer Netherlands",
number = "1-2",

}

TY - JOUR

T1 - Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats

AU - Vinitha, R.

AU - Thangaraju, Muthusamy

AU - Sachdanandam, P.

PY - 1997/3/6

Y1 - 1997/3/6

N2 - Tamoxifen, a non-steroidal anti-oestrogen, is used in the treatment of breast cancer, both receptor positive and negative tumours. It also possesses weak oestrogenic activity which forms the basis of this study. Tamoxifen (2 different dosages) was administered through diet (10 mg/kg diet and 20 mg/kg diet) to experimental atherosclerosis induced female rats to assess the effect of tamoxifen on plasma lipid levels, lipoprotein cholesterol level and on the activity of lipid metabolising enzymes. The plasma total lipid level was increased in atherosclerosis suffering animals compared to control animals with concomitant changes in the activity of lipid metabolising enzymes. HDL-cholesterol was decreased while LDL-cholesterol and VLDL-cholesterol were increased in the atherosclerosis induced group. Cholesterol and free cholesterol were decreased in tamoxifen treated groups while the other lipids show a moderate increase. HDL-cholesterol was increased but LDL-cholesterol was decreased in the tamoxifen treated groups. The higher dosage tamoxifen given group animals show significantly favourable results from therapy stand point when compared to diseased group.

AB - Tamoxifen, a non-steroidal anti-oestrogen, is used in the treatment of breast cancer, both receptor positive and negative tumours. It also possesses weak oestrogenic activity which forms the basis of this study. Tamoxifen (2 different dosages) was administered through diet (10 mg/kg diet and 20 mg/kg diet) to experimental atherosclerosis induced female rats to assess the effect of tamoxifen on plasma lipid levels, lipoprotein cholesterol level and on the activity of lipid metabolising enzymes. The plasma total lipid level was increased in atherosclerosis suffering animals compared to control animals with concomitant changes in the activity of lipid metabolising enzymes. HDL-cholesterol was decreased while LDL-cholesterol and VLDL-cholesterol were increased in the atherosclerosis induced group. Cholesterol and free cholesterol were decreased in tamoxifen treated groups while the other lipids show a moderate increase. HDL-cholesterol was increased but LDL-cholesterol was decreased in the tamoxifen treated groups. The higher dosage tamoxifen given group animals show significantly favourable results from therapy stand point when compared to diseased group.

KW - Atherosclerosis

KW - Enzymes

KW - Lipoprotein cholesterol

KW - Oestrogen

KW - Plasma lipids

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0031040523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031040523&partnerID=8YFLogxK

M3 - Article

C2 - 9062889

AN - SCOPUS:0031040523

VL - 168

SP - 13

EP - 19

JO - Molecular and Cellular Biochemistry

JF - Molecular and Cellular Biochemistry

SN - 0300-8177

IS - 1-2

ER -